Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals PLC (HKMPY)
OTHER OTC:HKMPY
Earnings Data
Report Date
Aug 06, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
2.17Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call outlines a clear strategic reset with substantial near-term investment (R&D, sales/marketing, capacity) and reorganizational changes that are expected to depress some margins and delay certain revenue ramps through 2026. At the same time, the company presented multiple concrete positives: solid group EBITDA (25%), a recovered Rx division (~20% margins and strong EBIT history), meaningful branded and MENA growth, an expanding RTU pipeline with encouraging early traction (TYZAVAN), a plan to materially grow CMO over the medium term, and a GBP 250m buyback. Management expresses confidence in returning injectables to stronger growth by 2027–2028 once investments and capacity projects (e.g., Bedford) come online. Overall, strategic actions and long-term prospects appear to outweigh near-term operational headwinds.Company Guidance
Strong overall profitability
Group EBITDA margin at ~25%, ahead of many competitors targeting ~22%, indicating robust overall profitability and cost structure.
Rx turnaround and margins
Generic/Rx business recovered under prior leadership to deliver ~GBP 200m EBIT historically and margins close to 20%; management expects continued solid performance and further margin improvement over time.
MENA and Branded growth
Hikma #1 in MENA this year; MENA reported strong growth and margins; Branded business guiding at ~7%–8% growth (up from prior ~5%–6%), and management signing multiple licensing/partnership deals (6 new biosimilars in MENA).
Injectables ready-to-use (RTU) platform progress
Pipeline of ~15 RTU products with TYZAVAN launch momentum described as 'active and encouraging' — TYZAVAN has already converted ~13% of the vancomycin gram market; large addressable market (~41m grams) and existing customer base penetration (~15% of sites).
Increased R&D commitment
Corporate R&D budget elevated and centralized with target spend of ~5%–6% of group sales; year-over-year R&D increase reported at roughly $45m and injectable-specific R&D up ~GBP 15m versus prior year to support pipeline and long-term growth.
CMO and capacity expansion plans
Rx CMO revenue ~10% this year with target to reach ~20% by 2030; Bedford (acquisition/Xellia) and Cherry Hill capacity projects underway to capture US onshoring demand, supporting medium-term CMO growth.
Capital allocation and shareholder returns
Board approved a share buyback of GBP 250m this year, signaling capital return intent alongside reinvestment plans.
Operational improvements and hiring
Management has reorganized to centralize R&D, hired new commercial and supply-chain leaders, and committed to devolved decision-making to accelerate investments, shorten decision cycles and reduce bottlenecks.
HKMPY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HKMPY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $44.72 | $37.10 | -17.02% |
Aug 07, 2025 | $49.50 | $46.23 | -6.60% |
Feb 26, 2025 | $56.24 | $52.94 | -5.87% |
Aug 08, 2024 | $44.79 | $48.46 | +8.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Hikma Pharmaceuticals PLC (HKMPY) report earnings?
Hikma Pharmaceuticals PLC (HKMPY) is schdueled to report earning on Aug 06, 2026, TBA (Confirmed).
What is Hikma Pharmaceuticals PLC (HKMPY) earnings time?
Hikma Pharmaceuticals PLC (HKMPY) earnings time is at Aug 06, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HKMPY EPS forecast?
Currently, no data Available